Abstract | OBJECTIVES: METHODS: In this longitudinal observational cohort study, 147 consecutive patients receiving monthly administration of erenumab or galcanezumab were enrolled in four Italian headache centers. All patients filled a questionnaire concerning working and household settings, recent flu symptoms or COVID-19 diagnosis, and family loss due to COVID-19 infection. Monthly migraine days (MMDs), monthly painkiller intake (MPI), and HIT-6 disability relative to the first month of lockdown imposition (T-lock) and the month before (T-free) were also collected. RESULTS: From T-free to T-lock, the cohort displayed a reduction in MMDs (from 10.5 ± 7.6 to 9.8 ± 7.6, p = .024) and HIT-6 scores (from 59.3 ± 8.3 men reduced MPI more frequently than women (p = .005). CONCLUSIONS: Our study observed that the lockdown impact to 57.8 ± 8.8, p = .009), while MPI resulted unchanged (from 11.6 ± 11.5 to 11.1 ± 11.7; p = .114). MMDs, MPI, and HIT-6 variations from T-free to T-lock did not differ according to work settings or household. Patients beyond the first 3 months of therapy presented less often a reduction in MMDs (p = .006) and on everyday life did not affect the migraine load in patients receiving monoclonal antibodies inhibiting the CGRP pathway. Patients in the first months of therapy experienced a greater improvement according to drug pharmacokinetics, while women more frequently needed rescue medications, possibly indicating presenteeism or cephalalgophobia.
|
Authors | Claudia Altamura, Sabina Cevoli, Cinzia Aurilia, Gabriella Egeo, Luisa Fofi, Paola Torelli, Nicoletta Brunelli, Giulia Pierangeli, Valentina Favoni, Adriana Fallacara, Umberto Pensato, Piero Barbanti, Fabrizio Vernieri |
Journal | Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
(Neurol Sci)
Vol. 41
Issue 12
Pg. 3385-3389
(Dec 2020)
ISSN: 1590-3478 [Electronic] Italy |
PMID | 33001407
(Publication Type: Journal Article, Multicenter Study, Observational Study)
|
Chemical References |
- Antibodies, Monoclonal, Humanized
- Calcitonin Gene-Related Peptide Receptor Antagonists
- galcanezumab
- erenumab
|
Topics |
- Adult
- Antibodies, Monoclonal, Humanized
(therapeutic use)
- COVID-19
- Calcitonin Gene-Related Peptide Receptor Antagonists
(therapeutic use)
- Cohort Studies
- Coronavirus Infections
(prevention & control)
- Female
- Humans
- Italy
(epidemiology)
- Longitudinal Studies
- Male
- Middle Aged
- Migraine Disorders
(drug therapy, epidemiology)
- Pandemics
(prevention & control)
- Pneumonia, Viral
(prevention & control)
- Quarantine
(psychology)
- Surveys and Questionnaires
|